Alnylam Pharmaceuticals (ALNY) Operating Expenses (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Operating Expenses came in at $1.1 billion in Q2 2026, up 34.13% YoY from $789.9 million in Q2 2025, and up 17.91% on a QoQ basis from $898.5 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Operating Expenses (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Operating Expenses data on file, last reported at $1.1 billion in Q2 2026.
- Quarterly Operating Expenses rose 34.13% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 billion (up 43.99% YoY) and the FY2025 annual result came in at $3.2 billion, up 32.46% from the prior year.
- Operating Expenses grew to $1.1 billion in Q2 2026, from $898.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $1.1 billion in Q2 2026 to a low of $360.0 million in Q1 2022.
- A 5-year average of $640.5 million and a median of $566.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses dropped 1.05% — and 2026, when it surged 55.97%.
- Tracing ALNY's Operating Expenses over 5 years: stood at $523.6 million in 2022, then grew by 6.2% to $556.1 million in 2023, then rose by 25.57% to $698.3 million in 2024, then jumped by 38.23% to $965.3 million in 2025, then climbed by 9.76% to $1.1 billion in 2026.
- The last three Operating Expenses figures came in at $1.1 billion (Q2 2026), $898.5 million (Q1 2026), and $965.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Bn |
| Mar 31, 2026 | 898.54 Mn |
| Dec 31, 2025 | 965.32 Mn |
| Sep 30, 2025 | 881.04 Mn |
| Jun 30, 2025 | 789.89 Mn |
| Mar 31, 2025 | 576.11 Mn |
| Dec 31, 2024 | 698.33 Mn |
| Sep 30, 2024 | 577.82 Mn |
| Jun 30, 2024 | 611.21 Mn |
| Mar 31, 2024 | 537.77 Mn |
| Dec 31, 2023 | 556.12 Mn |
| Sep 30, 2023 | 536.66 Mn |
| Jun 30, 2023 | 548.59 Mn |
| Mar 31, 2023 | 469.10 Mn |
| Dec 31, 2022 | 523.65 Mn |
| Sep 30, 2022 | 522.35 Mn |
| Jun 30, 2022 | 416.50 Mn |
| Mar 31, 2022 | 359.99 Mn |
| Dec 31, 2021 | 453.10 Mn |
| Sep 30, 2021 | 369.31 Mn |